
Investors should exercise extreme caution with MedV and the GLP-1 telehealth sector due to thin 15% margins, aggressive marketing tactics, and looming FDA regulatory scrutiny. In the AI space, monitor OpenAI for a potential IPO as early as Q4 2026, but be aware of their massive projected $121 billion compute spend through 2028. Anthropic’s acquisition of Coefficient Bio signals a high-conviction shift toward AI drug discovery, making biotech a primary value unlock for large language models. Within the defense sector, look for opportunities in "low-cost attritable systems" like the Lucas (FLM 136) drone, as the Pentagon shifts procurement toward cheaper, mass-produced autonomous weapons. Finally, the B2B stablecoin market is a high-growth area for 2025, with infrastructure providers like Better Money and Stripe benefiting from new regulatory clarity for instant corporate payouts.
• MedV is a telehealth provider specializing in GLP-1 weight loss drugs, recently gaining viral attention for being a "billion-dollar company" run by only one or two people. • Revenue vs. Valuation: The company is reportedly on track for $1.8 billion in sales (ARR), but analysts question the durability of this revenue and the actual market cap. • Operational Model: The company heavily outsources core functions (doctors, pharmacies, shipping, compliance) to third parties like Care Validate and Open Loop Health. • Regulatory Risks: The FDA recently issued a warning letter to MedV regarding misbranding. There are also reports of aggressive and potentially deceptive marketing, including the use of hundreds of fake "doctor" accounts on Facebook. • Legal Issues: The company is facing a class-action lawsuit for allegedly violating California's anti-spam laws.
• Margin Compression: While revenue is high, estimated margins are thin (around 15%). Investors should be wary of "one-person" unicorns that rely entirely on third-party infrastructure and aggressive customer acquisition costs (CAC). • Regulatory Scrutiny: The GLP-1 telehealth space is under intense FDA oversight. Companies pushing "compounded" versions of these drugs face significant legal and safety risks. • Marketing Durability: High growth fueled by "gray area" marketing (e.g., fake doctor profiles) is often non-durable and subject to platform bans or government intervention.
• Training Costs: Financial documents reveal a massive "Achilles heel"—the soaring cost of compute. OpenAI is projected to spend $121 billion on computing power by 2028. • Burn Rate: OpenAI anticipates burning $85 billion in 2028 alone, even as sales double. • IPO Speculation: There are internal tensions at OpenAI regarding IPO timing. CEO Sam Altman reportedly wants to go public as early as Q4 2026, while CFO Sarah Friar has voiced concerns over the ambitious spending plans. • Anthropic Acquisitions: Anthropic recently acquired Coefficient Bio for $400 million to build an AI drug R&D platform, signaling a major move into biotech and life sciences.
• Capital Intensity: Frontier AI is currently a "Capex war." Investors should monitor whether these companies can transition from massive research spend to sustainable cash flow before capital markets lose patience. • Biotech Integration: The acquisition of Coefficient Bio suggests that the next major value unlock for LLMs may be in drug discovery and clinical workflows.
• Pork Industry Overcapacity: China’s pork industry is suffering from massive oversupply. Companies have built "swine scrapers" (26-story high-rise pig farms) to increase yields, but domestic consumption is falling as the middle class shifts to seafood and poultry. • AI Talent Shift: For the first time, more studies at top AI conferences have lead authors based in China rather than the US. However, critics argue this is because US researchers at private labs (OpenAI/Google) have stopped publishing their best work. • Master Plan 2030: China is aggressively funding "frontier" tech including flying taxis (low-altitude economy), fusion power, humanoid robots, and brain-computer interfaces (BCI).
• Agricultural Tech: The "vertical farming" of livestock in China shows a massive industrial shift, but the resulting oversupply makes the sector a risky investment due to flatlining profits. • Strategic Competition: China is successfully dominating "mature" tech like EVs and batteries; the next decade's battleground is BCI and autonomous flight.
• Low-Cost Attritable Systems: The US military has successfully reverse-engineered Iranian drone technology to create the Lucas (FLM 136) drone. • Cost Efficiency: While a Tomahawk missile costs $2 million, the Lucas drone costs between $10,000 and $55,000. • Procurement Shift: The Pentagon is moving away from slow, expensive traditional contractors toward "second and third-tier" manufacturers to mass-produce cheap, autonomous weapons.
• Defense Tech Disruption: There is a major investment theme in "cheap and plentiful" vs. "expensive and exquisite." Startups that can manufacture at scale (like Specter Works or Integration Innovation) are gaining ground over traditional defense primes for specific use cases.
• Stablecoin Infrastructure: Better Money raised $10 million to build a stablecoin clearinghouse. • Corporate Adoption: Large payments companies are increasingly looking at stablecoins for treasury management, remittances, and instant payouts to avoid the 2-day lag of ACH. • Regulatory Clarity: The "Genius Act" (July 2025) has provided the regulatory framework needed for big institutions to finally integrate stablecoins into their stacks.
• B2B Stablecoin Use: The real growth in crypto is moving toward "boring" back-end infrastructure that solves working capital issues for gig-economy platforms (e.g., Stripe and Branch partnering for instant 1099 payouts).
• The game Balatro (a poker-themed roguelike) has sold over 5-7 million units, generating nearly $100 million in revenue for a solo developer. • This is cited as a "clean" example of a high-value, low-headcount business model that AI will likely accelerate in the gaming and software sectors.

By John Coogan & Jordi Hays
Technology's daily show (formerly the Technology Brothers Podcast). Streaming live on X and YouTube from 11 - 2 PM PST Monday - Friday. Available on X, Apple, Spotify, and YouTube.